Abstract
Background: The problem of bacterial resistance of Mycobacterium tuberculosis should be solved by seeking for alternative substances that potentially inhibit the growth or kill the bacteria. Ganoderma lucidum is one type of fungus which is potential to be an antimicrobial agent. This study aimed to determine the potential of G. lucidum on inhibiting the growth of multidrug-resistant bacteria of M. tuberculosis in vitro.
Methods: This study used a solid dilution method to test the extract of G. lucidum as an antibacterial agent.
Results and Conclusion: Results showed that all strains of multidrug-resistant tuberculosis (MDR-Tb) gave similar responses to G. lucidum extract at various concentrations. The bacteria did not grow on the medium containing G. lucidum extract at the smallest concentration of 12.5%, as well as concentrations of 25% and 50%. Ganoderma lucidum can be used as one of the alternatives for MDR-Tb drugs in the future.
Keywords: Antibacterial agent, Ganoderma lucidum, Mycobacterium tuberculosis, resistance, MDR-Tb, antimicrobialagents.
Graphical Abstract
Anti-Infective Agents
Title:The Potential of Ganoderma Lucidum as Antimicrobial Agent for Multidrug- Resistant Mycobacterium Tuberculosis
Volume: 16 Issue: 1
Author(s): Meira Erawati*, Megah Andriany and Niken Safitri Dyan Kusumaningrum
Affiliation:
- Faculty of Medicine, Diponegoro University, Semarang,Indonesia
Keywords: Antibacterial agent, Ganoderma lucidum, Mycobacterium tuberculosis, resistance, MDR-Tb, antimicrobialagents.
Abstract: Background: The problem of bacterial resistance of Mycobacterium tuberculosis should be solved by seeking for alternative substances that potentially inhibit the growth or kill the bacteria. Ganoderma lucidum is one type of fungus which is potential to be an antimicrobial agent. This study aimed to determine the potential of G. lucidum on inhibiting the growth of multidrug-resistant bacteria of M. tuberculosis in vitro.
Methods: This study used a solid dilution method to test the extract of G. lucidum as an antibacterial agent.
Results and Conclusion: Results showed that all strains of multidrug-resistant tuberculosis (MDR-Tb) gave similar responses to G. lucidum extract at various concentrations. The bacteria did not grow on the medium containing G. lucidum extract at the smallest concentration of 12.5%, as well as concentrations of 25% and 50%. Ganoderma lucidum can be used as one of the alternatives for MDR-Tb drugs in the future.
Export Options
About this article
Cite this article as:
Erawati Meira *, Andriany Megah and Kusumaningrum Safitri Dyan Niken , The Potential of Ganoderma Lucidum as Antimicrobial Agent for Multidrug- Resistant Mycobacterium Tuberculosis, Anti-Infective Agents 2018; 16 (1) . https://dx.doi.org/10.2174/2211352516666180227135043
DOI https://dx.doi.org/10.2174/2211352516666180227135043 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Drug Delivery to Macrophages in Parasitic Infections
Current Drug Delivery Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinsons Disease
Mini-Reviews in Medicinal Chemistry Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Vitamins Mediate Immunological Homeostasis and Diseases at the Surface of the Body
Endocrine, Metabolic & Immune Disorders - Drug Targets Progress in Structure-Based Design of EGFR Inhibitors
Current Drug Targets Nanocarriers Made from Non-Ionic Surfactants or Natural Polymers for Pulmonary Drug Delivery
Current Pharmaceutical Design Therapeutic Approaches Blocking Glycan Synthesis as Targeting Strategy for Malaria
Current Clinical Pharmacology New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes
Current Medicinal Chemistry How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets C-cinnamoyl Glycosides: An Emerging “Tail” for the Development of Selective Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry Transition States and Inhibitors of the Purine Nucleoside Phosphorylase Family
Current Topics in Medicinal Chemistry Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Recent Progress of Molecular Docking Simulations Applied to Development of Drugs
Current Bioinformatics Novel Drugs Targeting the c-Ring of the F<sub>1</sub>F<sub>O</sub>-ATP Synthase
Mini-Reviews in Medicinal Chemistry Demographic, Clinical and Laboratory Profiles of HIV Infected Patients Admitted into Imam Khomeini Hospital of Tehran, Iran
Infectious Disorders - Drug Targets Modular Organization in a Cell: Concepts and Applications
Current Bioinformatics In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
Current Pharmaceutical Design Coumarin-Oxadiazole Derivatives: Synthesis and Pharmacological Properties
Mini-Reviews in Organic Chemistry